What is Gyre Therapeutics' operating income?

Gyre Therapeutics' total operating income in 2025 was $11.49 million, based on the following breakdown: Total Gross Profit: $111.17 million Total Operating Expenses: $99.69 million

Gyre Therapeutics (GYRE) Financials

$6.68 +0.14 (+2.14%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$6.68 0.00 (-0.07%)

As of 08/14/2026 07:34 PM Eastern

Compare

Annual Income Statements for Gyre Therapeutics

This table shows Gyre Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-15	-17	-26	-30	-55	-56	-88	2.30	-93	12	5.03
Consolidated Net Income / (Loss)	-15	-17	-22	-30	-55	-56	-88	4.31	-85	18	9.88
Net Income / (Loss) Continuing Operations	-15	-17	-22	-30	-55	-56	-88	4.31	-85	18	9.88
Total Pre-Tax Income	-15	-17	-22	-30	-55	-56	-88	9.41	-77	23	14
Total Operating Income	-14	-20	-22	-34	-57	-57	-88	9.20	-67	16	11
Total Gross Profit	1.75	0.40	1.02	0.01	0.00	12	-0.04	97	109	102	111
Total Revenue	1.75	0.40	1.02	0.01	0.00	21	7.34	102	113	106	117
Operating Revenue	1.75	0.40	1.02	0.01	0.00	21	7.34	102	113	106	117
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	9.16	7.38	4.79	4.64	3.88	5.42
Operating Cost of Revenue	-	-	-	-	0.00	9.16	7.38	4.79	4.64	3.88	5.42
Total Operating Expenses	16	21	23	34	57	69	88	88	176	86	100
Selling, General & Admin Expense	9.59	9.26	9.99	12	13	16	19	17	15	16	21
Marketing Expense	-	-	-	-	-	-	-	54	61	58	65
Research & Development Expense	5.96	12	13	21	44	53	69	17	97	12	14
Other Special Charges / (Income)	-	-	-	-	-	-	0.00	0.00	0.63	0.07	0.00
Total Other Income / (Expense), net	-0.96	3.47	0.26	3.77	2.10	1.13	-0.04	0.21	-9.74	7.06	2.95
Interest Expense	0.96	-3.47	-0.26	-3.77	-2.10	-1.13	0.04	-0.73	-1.04	-1.55	-1.75
Other Income / (Expense), net	-	-	-	-	-	-	-	-0.52	-11	5.51	1.20
Income Tax Expense	-	-	-	-	-	-	0.00	5.10	8.52	5.32	4.56
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	-	-	-	2.01	7.45	5.81	4.85
Basic Earnings per Share	($49.99)	($21.75)	($7.45)	($2.68)	($4.60)	($2.93)	($2.87)	$0.04	($1.41)	$0.14	$0.06
Weighted Average Basic Shares Outstanding	295.27K	779.17K	3.42M	11.21M	12.00M	19.18M	30.64M	63.59M	65.83M	85.09M	89.34M
Diluted Earnings per Share	($49.99)	($21.75)	($7.45)	($2.68)	($4.60)	($2.93)	($2.87)	$0.03	($1.41)	$0.05	$0.02
Weighted Average Diluted Shares Outstanding	295.27K	779.17K	3.42M	11.21M	12.00M	19.18M	30.64M	75.69M	65.83M	102.29M	103.18M
Weighted Average Basic & Diluted Shares Outstanding	295.27K	779.17K	3.42M	11.21M	12.00M	19.18M	30.64M	37.76M	85.42M	93.61M	96.96M

This table shows Gyre Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-101	7.53	3.53	1.12	-0.10	2.70	-2.04	3.61	-1.72	-8.69	-12
Consolidated Net Income / (Loss)	-101	9.94	4.54	2.86	0.57	3.73	-2.24	5.94	-1.37	-9.86	-14
Net Income / (Loss) Continuing Operations	-101	9.94	4.54	2.86	0.57	3.73	-2.24	5.94	-1.37	-9.86	-14
Total Pre-Tax Income	-100	12	6.04	3.93	0.77	4.64	-1.58	7.63	-0.07	-9.24	-14
Total Operating Income	-92	8.07	3.19	4.23	0.60	2.27	-2.24	6.93	0.12	-9.36	-14
Total Gross Profit	26	26	24	25	27	21	29	29	35	21	27
Total Revenue	27	27	25	25	28	22	30	31	37	23	29
Operating Revenue	27	27	25	25	28	22	30	31	37	23	29
Total Cost of Revenue	1.25	0.98	0.77	0.96	1.18	0.89	1.15	1.63	1.74	1.23	2.21
Operating Cost of Revenue	1.25	0.98	0.77	0.96	1.18	0.89	1.15	1.63	1.74	1.23	2.21
Total Operating Expenses	117	18	21	20	26	19	31	22	35	31	41
Selling, General & Admin Expense	10	3.40	3.42	3.82	5.46	4.96	7.28	4.32	6.70	7.22	7.87
Marketing Expense	16	13	14	14	17	11	15	15	24	14	14
Research & Development Expense	88	2.18	3.36	2.78	3.71	3.10	8.35	2.36	4.82	6.74	19
Other Operating Expenses / (Income)	-	-	-	-	-	0.00	0.00	-	-	2.55	0.50
Total Other Income / (Expense), net	-9.17	4.41	2.84	-0.30	0.11	2.36	0.67	0.70	-0.18	0.12	-0.07
Interest Expense	-0.33	-	-	-	-0.35	-	-0.94	-	-	-	-0.74
Other Income / (Expense), net	-9.50	4.41	2.84	-0.30	-0.24	2.36	-0.28	0.70	-1.93	0.12	-0.81
Income Tax Expense	0.70	2.55	1.50	1.07	0.20	0.90	0.66	1.69	1.30	0.62	-0.16
Preferred Stock Dividends Declared	-	-	-	-	-	-	2.64	-	-	-	1.06
Net Income / (Loss) Attributable to Noncontrolling Interest	0.03	2.40	1.01	1.73	0.67	1.04	-2.84	2.33	0.36	-1.17	-3.67
Basic Earnings per Share	($1.54)	$0.09	$0.04	$0.01	-	$0.03	($0.02)	$0.04	($0.02)	($0.10)	($0.12)
Weighted Average Basic Shares Outstanding	65.83M	83.27M	85.50M	85.64M	85.09M	86.42M	89.12M	90.85M	89.34M	91.32M	100.64M
Diluted Earnings per Share	($1.51)	$0.03	$0.01	$0.01	-	$0.00	($0.03)	$0.03	($0.02)	($0.10)	($0.12)
Weighted Average Diluted Shares Outstanding	65.83M	102.59M	102.21M	102.64M	102.29M	101.97M	89.20M	103.97M	103.18M	91.34M	100.64M
Weighted Average Basic & Diluted Shares Outstanding	85.42M	85.51M	93.42M	93.52M	93.61M	93.76M	96.31M	96.33M	96.96M	97.03M	111.51M

This table details how cash moves in and out of Gyre Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	28	-19	-10	11	-16	15	14	-5.03	8.33	-22	25
Net Cash From Operating Activities	-19	-18	-20	-29	-44	-55	-84	11	26	-3.64	1.01
Net Cash From Continuing Operating Activities	-19	-18	-20	-29	-44	-55	-84	11	26	-3.64	0.99
Net Income / (Loss) Continuing Operations	-15	-17	-22	-30	-55	-56	-88	4.31	-85	18	9.88
Consolidated Net Income / (Loss)	-15	-17	-22	-30	-55	-56	-88	4.31	-85	18	9.88
Depreciation Expense	0.47	0.39	0.17	0.15	0.15	0.14	0.29	1.09	1.07	1.55	2.48
Amortization Expense	-	-	-	-	-	-	-	0.04	0.04	0.04	0.04
Non-Cash Adjustments To Reconcile Net Income	1.43	-2.75	0.88	2.72	3.20	3.63	3.41	14	105	-11	4.13
Changes in Operating Assets and Liabilities, net	-6.26	0.84	0.57	-1.37	8.22	-2.57	0.48	-8.64	4.76	-13	-16
Net Cash From Investing Activities	37	-1.31	-11	-71	27	9.66	48	-14	-20	-20	-0.47
Net Cash From Continuing Investing Activities	37	-1.31	-11	-71	27	9.66	48	-14	-20	-20	-0.47
Purchase of Property, Plant & Equipment	-0.27	-0.47	-0.02	-0.38	-	-	-0.84	-4.99	-8.52	-2.32	-1.19
Acquisitions	-	-	-	-	-	-	-	-1.35	-1.19	-2.50	-0.73
Sale of Property, Plant & Equipment	0.00	2.56	-	-	-	-	0.00	0.00	0.66	0.40	0.03
Sale and/or Maturity of Investments	14	10	14	128	157	108	49	-	-	0.00	15
Other Investing Activities, net	24	-0.01	-	-	-	-	0.00	-7.48	-16	-15	-14
Net Cash From Financing Activities	9.31	0.95	21	111	0.33	60	50	0.00	2.50	2.10	24
Net Cash From Continuing Financing Activities	9.31	0.95	21	111	0.33	60	50	0.00	2.50	2.10	24
Repayment of Debt	-3.02	-14	-14	-5.08	-	-	-	-	-	-0.54	-1.49
Issuance of Common Equity	0.00	0.96	5.34	-	0.33	60	49	-	0.00	0.77	24
Other Financing Activities, net	0.01	0.00	12	9.65	-	-	0.30	-	0.00	1.87	2.36
Effect of Exchange Rate Changes	-	-	-	-	-	-	-	-1.89	-0.30	-0.27	0.34
Cash Income Taxes Paid	-	-	-	-	-	-	-	6.31	6.35	8.52	5.62

This table details how cash moves in and out of Gyre Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	7.43	-3.72	-14	-0.23	-4.05	3.23	21	3.91	-3.33	0.43	-6.34
Net Cash From Operating Activities	3.36	2.88	-5.49	1.73	-2.76	-0.13	2.09	4.68	-5.63	3.18	-17
Net Cash From Continuing Operating Activities	3.36	2.88	-5.49	1.73	-2.76	-0.13	2.11	4.65	-5.63	3.18	-17
Net Income / (Loss) Continuing Operations	-101	9.94	4.54	2.86	0.57	3.73	1.58	5.94	-1.37	-9.86	-23
Consolidated Net Income / (Loss)	-101	9.94	4.54	2.86	0.57	3.73	1.58	5.94	-1.37	-9.86	-23
Depreciation Expense	0.30	0.42	0.23	0.45	0.46	0.54	0.64	0.65	0.66	0.67	1.48
Non-Cash Adjustments To Reconcile Net Income	104	-4.36	-2.67	0.15	-3.61	1.41	2.12	0.87	-0.25	5.49	9.92
Changes in Operating Assets and Liabilities, net	0.06	-3.10	-7.60	-1.73	-0.18	-5.81	-2.23	-2.81	-4.70	6.87	-5.14
Net Cash From Investing Activities	1.34	-7.22	-8.27	-2.39	-2.00	1.97	-3.04	-1.25	1.85	-3.06	9.76
Net Cash From Continuing Investing Activities	1.34	-7.22	-8.27	-2.39	-2.00	1.97	-3.04	-1.25	1.85	-3.06	9.76
Purchase of Property, Plant & Equipment	-2.32	-0.23	-1.46	-0.69	0.07	-0.12	-0.26	-0.67	-0.14	-0.18	-0.26
Acquisitions	-1.13	0.00	-	-0.00	-2.50	-0.70	-0.02	-0.02	0.00	-0.01	-1.02
Purchase of Investments	-	0.00	-	-	-	0.00	-	-	-	0.00	-2.03
Sale of Property, Plant & Equipment	0.17	0.05	0.22	-0.01	0.14	0.00	0.02	-	0.01	0.01	0.01
Sale and/or Maturity of Investments	-	0.00	-	-	-	11	-	-	4.24	10	16
Other Investing Activities, net	-1.97	-7.04	-7.04	-1.69	0.29	-8.40	-2.78	-	-2.83	-13	-2.92
Net Cash From Financing Activities	2.50	0.66	0.16	0.32	0.96	1.34	22	0.37	0.32	0.02	-0.01
Net Cash From Continuing Financing Activities	2.50	0.66	0.16	0.32	0.96	1.34	22	0.37	0.32	0.02	-0.01
Other Financing Activities, net	-	0.66	0.28	0.37	0.02	0.96	1.03	0.05	0.32	0.02	-0.01
Effect of Exchange Rate Changes	0.23	-0.05	-0.08	-	-	0.05	-	-	0.13	0.29	0.64

This table presents Gyre Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	70	38	40	125	99	95	56	85	117	125	220
Total Current Assets	69	38	39	124	96	90	51	50	57	65	149
Cash & Equivalents	29	10	14	31	15	30	44	25	34	12	49
Short-Term Investments	3.40	6.80	18	89	61	49	2.50	-	0.00	15	43
Note & Lease Receivable	-	-	-	-	-	-	-	17	0.39	9.33	5.64
Accounts Receivable	0.49	0.03	-	-	15	3.31	1.82	0.00	16	20	31
Inventories, net	-	-	-	-	-	-	-	6.12	4.28	6.34	10
Prepaid Expenses	1.78	0.96	1.33	3.81	4.20	6.84	2.81	0.38	1.55	1.19	9.61
Plant, Property, & Equipment, net	0.70	0.44	0.28	0.39	0.30	0.43	0.97	18	23	24	28
Total Noncurrent Assets	0.13	0.13	0.13	0.54	2.18	4.90	3.22	17	36	37	43
Intangible Assets	-	-	-	-	-	-	-	0.30	0.21	0.27	4.73
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	4.08	4.70	5.62	6.87
Other Noncurrent Operating Assets	-	0.13	0.13	0.54	2.18	2.36	3.22	13	26	31	31
Total Liabilities & Shareholders' Equity	70	38	40	125	99	95	56	85	117	125	220
Total Liabilities	38	22	8.74	4.98	30	19	15	13	38	27	31
Total Current Liabilities	38	22	8.74	4.80	29	18	14	12	20	20	24
Accounts Payable	0.94	0.84	0.75	1.25	4.28	5.93	6.42	0.12	0.36	0.11	1.34
Accrued Expenses	0.54	0.81	1.32	2.04	7.03	6.74	4.07	9.26	12	11	18
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	-	2.10	5.05	2.83	2.94
Other Current Liabilities	1.16	-	-	-	0.48	0.66	1.98	0.61	2.70	5.96	1.35
Total Noncurrent Liabilities	0.34	0.05	0.00	0.17	1.32	0.98	0.41	0.29	18	7.49	7.62
Noncurrent Deferred Revenue	0.34	0.05	0.00	0.17	-	-	-	0.12	0.21	0.93	0.85
Other Noncurrent Operating Liabilities	-	-	-	-	1.32	0.98	0.41	0.18	18	6.56	6.77
Commitments & Contingencies	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	-	-	-	0.00	0.00	65	0.00	129
Total Equity & Noncontrolling Interests	31	16	31	120	68	76	41	72	14	98	60
Total Preferred & Common Equity	31	16	31	120	68	76	41	43	-16	63	62
Total Common Equity	31	16	31	120	68	76	41	43	-16	63	62
Common Stock	162	164	204	323	327	391	444	33	68	136	173
Retained Earnings	-131	-148	-173	-203	-259	-315	-403	7.40	-86	-73	-113
Accumulated Other Comprehensive Income / (Loss)	0.00	-0.00	0.00	-0.00	0.03	0.01	-	-0.39	-1.64	-2.60	-0.91
Other Equity Adjustments	-	-	-	-	-	-	-	2.66	3.10	3.10	3.10
Noncontrolling Interest	-	-	-	-	-	-	-	30	30	35	-2.95

This table presents Gyre Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	19	12	9.96	122	121	125	130	153	159	162	199
Total Current Assets	14	7.62	5.13	63	54	55	68	91	99	92	122
Cash & Equivalents	8.10	6.92	2.23	30	16	16	15	36	40	38	43
Short-Term Investments	-	-	-	7.57	9.00	9.23	15	18	20	12	32
Note & Lease Receivable	-	-	-	15	19	19	2.14	0.50	0.69	3.82	0.23
Accounts Receivable	5.00	0.00	1.20	1.29	1.29	1.29	20	25	26	23	28
Inventories, net	-	-	-	4.94	5.64	6.38	7.88	8.86	8.85	11	11
Prepaid Expenses	0.92	0.70	1.70	1.79	1.15	1.05	8.16	2.70	2.87	3.76	7.60
Plant, Property, & Equipment, net	0.00	0.00	0.00	24	24	24	24	23	24	24	27
Total Noncurrent Assets	4.74	4.77	4.83	36	44	46	38	38	37	47	50
Intangible Assets	-	-	-	0.20	0.19	0.18	5.08	4.96	4.85	4.63	4.53
Noncurrent Deferred & Refundable Income Taxes	-	-	-	5.00	5.08	5.16	5.82	6.13	6.71	7.72	9.28
Other Noncurrent Operating Assets	0.19	0.17	0.17	26	34	36	27	27	26	34	36
Total Liabilities & Shareholders' Equity	19	12	9.96	122	121	125	130	153	159	162	199
Total Liabilities	11	7.40	6.45	33	28	27	25	23	22	25	34
Total Current Liabilities	6.84	2.79	1.78	19	16	15	19	17	16	20	29
Accounts Payable	0.02	0.01	0.16	0.33	0.27	0.30	0.12	0.07	0.56	0.27	1.24
Accrued Expenses	0.74	2.07	0.92	11	11	9.55	17	15	12	15	19
Current Deferred & Payable Income Tax Liabilities	-	-	-	6.47	2.26	2.84	0.57	1.08	2.65	3.13	2.15
Other Current Liabilities	5.00	0.00	0.00	1.88	2.47	1.98	1.03	0.84	0.91	0.98	6.47
Total Noncurrent Liabilities	4.55	4.61	4.66	14	12	12	6.50	6.28	6.06	5.24	5.67
Noncurrent Deferred Revenue	-	-	-	0.20	0.19	0.19	0.91	0.88	0.87	0.84	0.83
Other Noncurrent Operating Liabilities	4.55	4.61	4.66	14	12	12	5.59	5.40	5.19	4.40	4.84
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	33	33	0.00	0.00	0.00	0.00	-	-	-	-	22
Total Equity & Noncontrolling Interests	-26	-28	3.52	89	93	98	104	129	137	137	142
Total Preferred & Common Equity	-26	-28	3.52	57	60	63	68	92	102	101	108
Total Common Equity	-26	-28	-30	57	60	63	68	92	102	101	108
Common Stock	385	385	385	133	134	134	138	162	167	175	241
Retained Earnings	-411	-413	-415	-78	-74	-73	-71	-70	-67	-78	-138
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-1.74	-2.01	-0.95	-2.49	-2.29	-1.70	0.59	1.49
Other Equity Adjustments	-	-	-	3.10	3.10	3.10	3.10	3.10	3.10	3.65	3.65
Noncontrolling Interest	-	-	-	32	33	35	36	37	35	36	35

This table displays calculated financial ratios and metrics derived from Gyre Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	96,333,157.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	96,333,157.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.05
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-9.66	-14	-15	-24	-40	-40	-62	4.22	-47	12	7.86
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-337.38%	12.66%	5.53%
Earnings before Interest and Taxes (EBIT)	-14	-20	-22	-34	-57	-57	-88	8.69	-78	22	13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-13	-20	-22	-34	-57	-57	-88	9.82	-77	23	15
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-10	-14	-14	-25	-32	-43	-62	-49	-45	-14	-10
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1.25	-1.06	-1.92	-0.23	-8.53	-5.83	-5.76	47	45	72	90
Increase / (Decrease) in Invested Capital	0.82	0.19	-0.86	1.69	-8.30	2.70	0.07	53	-2.08	27	18
Book Value per Share	$2.75	$1.34	$7.14	$10.04	$5.68	$3.44	$1.31	$1.35	($0.42)	$0.68	$1.10
Tangible Book Value per Share	$2.75	$1.34	$7.14	$10.04	$5.68	$3.44	$1.31	$1.34	($0.42)	$0.67	$1.05
Total Capital	65	35	36	120	68	76	41	72	78	98	142
Total Debt	34	19	5.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-33	-17	-33	-120	-77	-82	-47	-25	-34	-27	-52
Capital Expenditures (CapEx)	0.27	-2.10	0.02	0.38	0.00	0.00	0.84	4.99	7.85	1.91	1.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.61	-1.57	-2.32	-0.99	-9.70	-7.64	-9.54	12	3.67	19	32
Debt-free Net Working Capital (DFNWC)	65	35	35	119	67	72	37	37	37	45	84
Net Working Capital (NWC)	31	16	30	119	67	72	37	37	37	45	84
Net Nonoperating Expense (NNE)	5.10	2.65	6.29	6.38	15	16	26	-0.10	38	-5.44	-2.02
Net Nonoperating Obligations (NNO)	-33	-17	-33	-120	-77	-82	-47	-25	-34	-27	-52
Total Depreciation and Amortization (D&A)	0.47	0.39	0.17	0.15	0.15	0.14	0.29	1.13	1.11	1.59	2.52
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($49.95)	($21.75)	($7.45)	($2.68)	$0.00	($2.93)	($2.87)	($0.26)	($1.41)	$0.14	$0.06
Adjusted Weighted Average Basic Shares Outstanding	762.01K	1.00M	11.89M	11.97M	0.00	31.33M	31.48M	31.55M	65.83M	85.09M	89.34M
Adjusted Diluted Earnings per Share	($49.95)	($21.75)	($7.45)	($2.68)	$0.00	($2.93)	($2.87)	($0.26)	($1.41)	$0.05	$0.02
Adjusted Weighted Average Diluted Shares Outstanding	762.01K	1.00M	11.89M	11.97M	0.00	31.33M	31.48M	31.55M	65.83M	102.29M	103.18M
Adjusted Basic & Diluted Earnings per Share	($49.95)	($21.75)	($7.45)	($2.68)	$0.00	($2.93)	($2.87)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	295.27K	779.17K	3.42M	11.21M	0.00	19.18M	30.64M	37.76M	85.42M	93.61M	96.96M
Normalized Net Operating Profit after Tax (NOPAT)	-9.66	-14	-15	-24	-40	-40	-62	6.44	-47	13	7.86
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Gyre Therapeutics' official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	96,333,157.00	96,963,611.00	97,028,322.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	96,333,157.00	96,963,611.00	97,028,322.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-0.02	-0.09	-0.12
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-73.25%	8.99%	-13.99%	-20.45%	2.67%	-18.82%	6.13%	19.92%	-	2.09%	-2.12%
EBITDA Growth	-366.92%	97.36%	1.18%	-66.81%	100.82%	-59.91%	-54.03%	89.21%	-	-265.67%	-808.49%
EBIT Growth	-350.27%	99.66%	2.68%	-70.20%	100.35%	-62.86%	-62.92%	94.12%	-	-299.29%	-503.10%
NOPAT Growth	-307.98%	43.37%	-23.43%	-64.10%	100.69%	-71.50%	-36.34%	75.16%	-	-457.62%	-541.21%
Net Income Growth	-261.95%	135.59%	20.37%	-61.97%	100.56%	-62.42%	-65.27%	107.84%	-	-364.01%	-537.91%
EPS Growth	-52.53%	0.00%	-50.00%	-80.00%	0.00%	-100.00%	-100.00%	200.00%	-	0.00%	-300.00%
Operating Cash Flow Growth	-92.06%	-72.31%	-221.18%	-77.24%	-182.08%	-104.47%	138.01%	170.92%	-	2,565.12%	-123.82%
Free Cash Flow Firm Growth	9.43%	-1,723.13%	-869.62%	-608.83%	57.58%	53.73%	92.18%	102.03%	-	8.73%	-198.80%
Invested Capital Growth	-4.42%	7,020.46%	3,639.73%	5,592.94%	59.53%	44.72%	10.01%	5.43%	-	17.16%	20.04%
Revenue Q/Q Growth	-15.27%	-54.09%	-7.17%	1.04%	9.35%	-20.86%	21.37%	14.17%	-	-39.46%	29.25%
EBITDA Q/Q Growth	-966.69%	116.51%	-52.37%	-35.55%	-78.53%	523.64%	-44.31%	187.53%	-	-640.28%	-59.85%
EBIT Q/Q Growth	-984.70%	115.73%	-52.66%	-40.78%	-89.49%	1,194.69%	-51.72%	240.88%	-	-409.49%	-64.27%
NOPAT Q/Q Growth	-848.64%	111.88%	-61.82%	25.41%	-85.70%	316.15%	-16.51%	252.44%	-	-8,027.97%	-53.53%
Net Income Q/Q Growth	-1,444.57%	110.81%	-54.32%	-37.06%	-80.08%	556.24%	-57.79%	276.65%	-	-621.67%	-44.76%
EPS Q/Q Growth	-3,120.00%	102.11%	-66.67%	0.00%	0.00%	0.00%	0.00%	0.00%	-	-400.00%	-20.00%
Operating Cash Flow Q/Q Growth	-55.68%	-92.37%	-290.46%	131.42%	-259.79%	95.32%	1,718.60%	123.95%	-	156.53%	-626.04%
Free Cash Flow Firm Q/Q Growth	-557.58%	12.03%	-48.07%	-1.91%	61.86%	19.62%	74.94%	126.48%	-	-7.04%	-29.95%
Invested Capital Q/Q Growth	3,388.36%	14.35%	32.73%	7.53%	-2.25%	3.74%	0.90%	3.05%	-	-2.98%	3.38%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	95.40%	96.40%	96.95%	96.24%	95.78%	95.95%	95.70%	94.67%	-	94.55%	92.41%
EBITDA Margin	-371.38%	46.29%	23.75%	15.15%	2.97%	23.44%	10.75%	27.08%	-	-38.03%	-47.04%
Operating Margin	-337.53%	29.70%	12.93%	16.61%	2.14%	10.30%	8.11%	22.66%	-	-41.54%	-49.35%
EBIT Margin	-372.51%	44.73%	22.81%	13.37%	1.28%	21.01%	8.36%	24.96%	-	-41.02%	-52.14%
Profit (Net Income) Margin	-371.95%	36.56%	17.99%	11.21%	2.04%	16.93%	5.89%	19.42%	-	-43.78%	-49.03%
Tax Burden Percent	100.70%	79.60%	75.19%	72.67%	73.70%	80.56%	70.42%	77.81%	-	106.72%	98.86%
Interest Burden Percent	99.16%	102.70%	104.90%	115.35%	215.64%	100.00%	100.00%	100.00%	-	100.00%	95.12%
Effective Tax Rate	0.00%	20.40%	24.81%	27.33%	26.30%	19.44%	29.58%	22.19%	-	0.00%	0.00%
Return on Invested Capital (ROIC)	-582.67%	107.96%	32.72%	33.95%	2.86%	13.28%	8.14%	25.09%	-	-42.13%	-48.69%
ROIC Less NNEP Spread (ROIC-NNEP)	-457.13%	92.51%	19.70%	35.57%	2.43%	7.62%	8.02%	23.80%	-	-33.82%	-42.16%
Return on Net Nonoperating Assets (RNNOA)	178.02%	-43.74%	-6.42%	-9.53%	-0.83%	-2.65%	-2.86%	-8.59%	-	11.17%	18.50%
Return on Equity (ROE)	-404.65%	64.22%	26.31%	24.43%	2.03%	10.63%	5.28%	16.50%	-	-30.96%	-30.19%
Cash Return on Invested Capital (CROIC)	-97.78%	-191.05%	-172.10%	-335.71%	-24.52%	-24.01%	0.30%	7.06%	-	-14.65%	-28.61%
Operating Return on Assets (OROA)	-419.90%	73.52%	38.18%	20.77%	1.12%	16.80%	6.25%	18.81%	-	-32.91%	-34.50%
Return on Assets (ROA)	-419.27%	60.10%	30.11%	17.41%	1.78%	13.53%	4.40%	14.64%	-	-35.12%	-32.44%
Return on Common Equity (ROCE)	-71.68%	20.50%	8.57%	8.00%	0.55%	6.87%	3.61%	11.55%	-	-21.74%	-20.51%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-140.82%	-130.89%	-132.40%	0.00%	17.17%	0.00%	0.00%	-	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-64	6.42	2.45	3.08	0.44	1.83	1.53	5.39	0.08	-6.55	-10
NOPAT Margin	-236.27%	23.64%	9.72%	12.07%	1.58%	8.30%	5.71%	17.63%	-	-29.08%	-34.54%
Net Nonoperating Expense Percent (NNEP)	-125.54%	15.45%	13.02%	-1.61%	0.43%	5.66%	0.12%	1.29%	-	-8.31%	-6.53%
Return On Investment Capital (ROIC_SIMPLE)	-459.84%	-	-	-	0.45%	1.76%	1.18%	3.92%	0.06%	-4.78%	-7.06%
Cost of Revenue to Revenue	4.60%	3.60%	3.05%	3.76%	4.22%	4.05%	4.30%	5.33%	-	5.45%	7.59%
SG&A Expenses to Revenue	37.04%	12.51%	13.57%	15.00%	19.60%	22.46%	18.04%	14.13%	-	32.06%	27.03%
R&D to Revenue	322.94%	8.03%	13.30%	10.89%	13.32%	14.03%	12.79%	7.73%	-	29.92%	65.75%
Operating Expenses to Revenue	430.99%	66.69%	84.29%	79.63%	93.39%	85.64%	87.59%	72.02%	-	136.09%	141.76%
Earnings before Interest and Taxes (EBIT)	-101	12	5.75	3.41	0.36	4.64	2.24	7.63	-1.81	-9.24	-15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-101	13	5.99	3.86	0.83	5.17	2.88	8.28	-1.16	-8.57	-14
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	26.36	16.90	18.54	17.87	10.61	7.49	7.05	-	6.67	5.92
Price to Tangible Book Value (P/TBV)	0.00	26.45	16.96	18.60	17.95	11.46	7.92	7.40	-	6.99	6.18
Price to Revenue (P/Rev)	8.60	12.91	9.14	11.15	10.70	7.18	6.74	6.70	-	5.77	5.49
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	93.64	99.67	165.45	108.03	-	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	1.07%	1.00%	0.60%	0.93%	-	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	23.05	28.94	15.06	16.10	15.89	9.80	8.95	8.97	-	7.59	6.90
Enterprise Value to Revenue (EV/Rev)	9.14	12.86	9.21	11.25	10.78	7.24	6.58	6.47	-	5.65	5.34
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	49.01	46.93	55.51	43.34	-	448.92	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	52.61	52.73	67.03	50.55	-	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	91.50	92.43	95.34	74.55	-	713.04	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	40.03	81.05	123.37	477.09	0.00	0.00	725.10	178.99	-	153.21	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	3,085.04	130.32	-	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Financial Leverage	-0.39	-0.47	-0.33	-0.27	-0.34	-0.35	-0.36	-0.36	-	-0.33	-0.44
Leverage Ratio	1.34	1.46	1.36	1.33	1.37	1.30	1.23	1.21	-	1.21	1.20
Compound Leverage Factor	1.32	1.50	1.42	1.53	2.95	1.30	1.23	1.21	-	1.21	1.14
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Noncontrolling Interests to Total Capital	120.17%	36.20%	35.35%	35.84%	35.65%	34.69%	28.91%	25.83%	-	26.04%	34.56%
Common Equity to Total Capital	-20.17%	63.80%	64.65%	64.16%	64.35%	65.31%	71.09%	74.17%	-	73.96%	65.44%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Altman Z-Score	12.84	27.76	22.78	26.75	25.61	17.60	18.48	20.49	-	16.60	11.10
Noncontrolling Interest Sharing Ratio	82.29%	68.08%	67.42%	67.26%	73.15%	35.38%	31.60%	30.01%	-	29.78%	32.07%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.85	3.22	3.44	3.72	3.32	3.60	5.40	6.19	-	4.64	4.26
Quick Ratio	2.51	2.78	2.89	3.12	2.86	2.76	4.71	5.46	-	3.87	3.60
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-62	-46	-68	-69	-26	-21	-5.30	1.40	-18	-19	-25
Operating Cash Flow to CapEx	155.77%	1,593.37%	-443.70%	247.28%	0.00%	-106.61%	877.31%	700.00%	-	1,848.84%	-6,560.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.13	1.64	1.67	1.55	0.87	0.80	0.75	0.75	-	0.80	0.66
Accounts Receivable Turnover	0.00	36.80	0.00	84.47	5.83	9.29	7.82	7.83	-	5.40	4.40
Inventory Turnover	0.89	0.00	0.00	0.00	0.73	0.59	0.58	0.64	-	0.60	0.67
Fixed Asset Turnover	5.53	9.82	0.00	0.00	4.48	4.28	4.34	4.46	-	4.97	4.59
Accounts Payable Turnover	19.44	25.95	30.31	17.17	16.78	16.81	24.44	11.29	-	29.71	10.42
Days Sales Outstanding (DSO)	0.00	9.92	0.00	4.32	62.59	39.29	46.69	46.61	-	67.63	82.89
Days Inventory Outstanding (DIO)	409.52	0.00	0.00	0.00	498.91	615.72	632.90	573.20	-	610.45	543.96
Days Payable Outstanding (DPO)	18.78	14.06	12.04	21.26	21.76	21.71	14.93	32.32	-	12.29	35.04
Cash Conversion Cycle (CCC)	390.75	-4.15	-12.04	-16.94	539.75	633.29	664.66	587.49	-	665.79	591.80
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	45	51	68	73	72	74	75	77	90	87	90
Invested Capital Turnover	2.47	4.57	3.37	2.81	1.81	1.60	1.43	1.42	-	1.45	1.41
Increase / (Decrease) in Invested Capital	-2.08	52	70	72	27	23	6.83	3.98	18	13	15
Enterprise Value (EV)	1,036	1,488	1,028	1,182	1,140	729	672	694	-	662	622
Market Capitalization	976	1,493	1,020	1,172	1,132	723	689	718	-	676	639
Book Value per Share	($0.42)	$0.66	$0.71	$0.68	$0.68	$0.73	$0.98	$1.06	$1.10	$1.04	$1.11
Tangible Book Value per Share	($0.42)	$0.66	$0.70	$0.67	$0.67	$0.67	$0.93	$1.01	$1.05	$1.00	$1.07
Total Capital	78	89	93	98	98	104	129	137	142	137	165
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-34	-37	-25	-25	-27	-30	-54	-60	-52	-50	-75
Capital Expenditures (CapEx)	2.16	0.18	1.24	0.70	-0.20	0.12	0.24	0.67	0.13	0.17	0.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)	3.67	5.89	13	15	19	20	20	23	32	22	19
Debt-free Net Working Capital (DFNWC)	37	43	38	40	45	49	74	83	84	72	93
Net Working Capital (NWC)	37	43	38	40	45	49	74	83	84	72	93
Net Nonoperating Expense (NNE)	37	-3.51	-2.09	0.22	-0.13	-1.90	-0.05	-0.55	1.45	3.31	4.22
Net Nonoperating Obligations (NNO)	-34	-37	-25	-25	-27	-30	-54	-60	-52	-50	-75
Total Depreciation and Amortization (D&A)	0.31	0.43	0.24	0.45	0.47	0.54	0.64	0.65	0.66	0.67	1.48
Debt-free, Cash-free Net Working Capital to Revenue	3.23%	5.09%	11.51%	14.28%	17.59%	19.44%	19.57%	21.08%	-	18.91%	15.99%
Debt-free Net Working Capital to Revenue	32.77%	37.37%	34.00%	38.17%	42.81%	49.14%	72.77%	77.06%	-	61.46%	80.23%
Net Working Capital to Revenue	32.77%	37.37%	34.00%	38.17%	42.81%	49.14%	72.77%	77.06%	-	61.46%	80.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.54)	$0.09	$0.04	$0.01	$0.00	$0.03	$0.00	$0.04	($0.02)	($0.10)	($0.12)
Adjusted Weighted Average Basic Shares Outstanding	65.83M	83.27M	85.50M	85.64M	85.09M	86.42M	89.12M	90.85M	89.34M	91.32M	100.64M
Adjusted Diluted Earnings per Share	($1.51)	$0.03	$0.01	$0.01	$0.00	$0.00	$0.00	$0.03	($0.02)	($0.10)	($0.12)
Adjusted Weighted Average Diluted Shares Outstanding	65.83M	102.59M	104.33M	102.64M	102.29M	101.97M	102.70M	103.97M	103.18M	91.34M	100.64M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($0.02)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	85.42M	85.51M	93.42M	93.52M	93.61M	93.76M	96.31M	96.33M	96.96M	97.03M	111.51M
Normalized Net Operating Profit after Tax (NOPAT)	-64	6.42	2.50	3.08	0.44	1.83	1.53	5.39	0.08	-6.55	-10
Normalized NOPAT Margin	-236.27%	23.64%	9.93%	12.07%	1.58%	8.30%	5.71%	17.63%	-	-29.08%	-34.54%
Pre Tax Income Margin	-369.38%	45.93%	23.92%	15.42%	2.77%	21.01%	8.36%	24.96%	-	-41.02%	-49.59%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Gyre Therapeutics’ first quarter 2026 results show a clear improvement in operating cash generation, but profitability remains under pressure from heavy marketing and operating costs.

The company generated $3.2 million in operating cash flow in Q1 2026, a sharp improvement from negative $5.6 million in Q4 2025 and positive $0.4 million in Q1 2025.
Revenue rose to $22.5 million in Q1 2026 from $22.1 million in Q1 2025, showing modest top-line growth year over year.
Gross profit remained strong at $21.3 million, with gross margin still robust despite a lower revenue base than late 2025.
The balance sheet remains liquid, with $37.5 million in cash and equivalents plus $12.3 million in short-term investments.
Total current assets of $91.7 million comfortably exceed total current liabilities of $19.8 million, suggesting near-term financial flexibility.
Q1 2026 net loss attributable to common shareholders was $8.7 million, or -$0.10 per share, which is worse than the prior-year quarter’s profit.
Accounts receivable climbed to $23.0 million, up from $20.4 million in Q1 2025, which may indicate higher sales but also more capital tied up in collections.
Inventory increased to $11.4 million from $7.9 million a year earlier, a sign the company is carrying more product on the balance sheet.
Marketing expense remains very high at $14.1 million in Q1 2026, far above R&D and SG&A, and continues to weigh heavily on earnings.
Operating loss was $9.4 million in Q1 2026, compared with operating income of $2.3 million in Q1 2025, showing that cost discipline remains a major issue.

Bottom line: Gyre Therapeutics appears to be improving cash generation and still has a solid liquidity cushion, but the business is not consistently profitable yet. Investors will likely want to see whether operating cash flow can stay positive while marketing and operating expenses come down relative to revenue.

08/16/26 03:02 AM ETAI Generated. May Contain Errors.

Gyre Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Gyre Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Gyre Therapeutics' net income appears to be on a downward trend, with a most recent value of $9.88 million in 2025, falling from -$14.76 million in 2015. The previous period was $17.90 million in 2024. View Gyre Therapeutics' forecast to see where analysts expect Gyre Therapeutics to go next.

Gyre Therapeutics' total operating income in 2025 was $11.49 million, based on the following breakdown:

Total Gross Profit: $111.17 million
Total Operating Expenses: $99.69 million

Over the last 10 years, Gyre Therapeutics' total revenue changed from $1.75 million in 2015 to $116.59 million in 2025, a change of 6,562.2%.

Gyre Therapeutics' total liabilities were at $31.40 million at the end of 2025, a 16.3% increase from 2024, and a 17.6% decrease since 2015.

In the past 10 years, Gyre Therapeutics' cash and equivalents has ranged from $10.26 million in 2016 to $49.19 million in 2025, and is currently $49.19 million as of their latest financial filing in 2025.

Over the last 10 years, Gyre Therapeutics' book value per share changed from 2.75 in 2015 to 1.10 in 2025, a change of -60.0%.

Related Companies

Financial statements for NASDAQ:GYRE last updated on 8/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gyre Therapeutics (GYRE) Financials

Financials Breakdown Chart

Key Financial Trends

Gyre Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gyre Therapeutics (GYRE) Financials

Annual Income Statements for Gyre Therapeutics

Quarterly Income Statements for Gyre Therapeutics

Annual Cash Flow Statements for Gyre Therapeutics

Quarterly Cash Flow Statements for Gyre Therapeutics

Annual Balance Sheets for Gyre Therapeutics

Quarterly Balance Sheets for Gyre Therapeutics

Annual Metrics And Ratios for Gyre Therapeutics

Quarterly Metrics And Ratios for Gyre Therapeutics

Financials Breakdown Chart

Key Financial Trends

Gyre Therapeutics Financials - Frequently Asked Questions

When does Gyre Therapeutics' fiscal year end?

How has Gyre Therapeutics' net income changed over the last 10 years?

What is Gyre Therapeutics' operating income?

How has Gyre Therapeutics' revenue changed over the last 10 years?

How much debt does Gyre Therapeutics have?

How much cash does Gyre Therapeutics have?

How has Gyre Therapeutics' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools